VB

Vincent Brichard

Senior Vice-president at GlaxoSmithKline Biologicals

Brussels Metropolitan Area

Investor

Invests in

Locations:

Brussels

  • Min Investment:

    $1,000,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Clinical Trials
Oncology
Biotechnology
Infectious Diseases
Vaccines
Immunology
Medicine
Clinical Development
Life Sciences
Market Access
Drug Development
Diabetes
Biopharmaceuticals
Drug Discovery

Education

Investments

Minervax

Series Unknown

Total Funding: $140M

ImCheck Therapeutics

Series B

Total Funding: $180M

Egle Therapeutics

Series A

Total Funding: $47M

FoRx Therapeutics

Seed

Total Funding: $11M

Work Experience

GlaxoSmithKline Biologicals

2002

  • Senior Vice-President

    2002

    Head of Immunotherapeutics Business Units (including antigen-sepcific cancer immunotherapy and other Therapeutic vaccines, e.g. against Alzheimer's, diabetes, multiple sclerosis or smoking cessation

Louvain University Medical Oncology Unit

2000 - 2002

  • Oncologist/Tumor immunology

    2000 - 2002

    oncologist

Institut Curie

1998 - 2000

  • Medical Oncology Department

    1998 - 2000

    Medical Oncology/Tumor immunology